Detalles de la búsqueda
1.
Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70.
Circulation
; 145(18): 1377-1386, 2022 05 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35369705
2.
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
N Engl J Med
; 383(15): 1425-1435, 2020 10 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32966714
3.
Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
Circulation
; 142(23): 2205-2215, 2020 12 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33026243
4.
Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials.
Diabetologia
; 63(6): 1128-1140, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32236732
5.
Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus.
Diabetes Obes Metab
; 22(4): 574-582, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31797522
6.
Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phase III studies.
Diabetes Obes Metab
; 22(12): 2276-2286, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32700421
7.
Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials.
Cardiovasc Diabetol
; 18(1): 59, 2019 05 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31064361
8.
Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial.
Diabetes Obes Metab
; 21(4): 1027-1036, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30614616
9.
Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia.
Diabetes Obes Metab
; 21(6): 1474-1482, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30830724
10.
A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjectsâ©.
Int J Clin Pharmacol Ther
; 57(4): 207-216, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30802200
11.
Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV).
Am Heart J
; 206: 11-23, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30290289
12.
Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study.
Diabetes Obes Metab
; 20(6): 1453-1460, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29419917
13.
Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).
Diabetes Obes Metab
; 20(3): 520-529, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28857451
14.
Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
Diabetes Obes Metab
; 20(5): 1111-1120, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29266675
15.
Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study.
Diabetes Obes Metab
; 20(3): 530-540, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28921862
16.
Examination of the Human Cytochrome P4503A4 Induction Potential of PF-06282999, an Irreversible Myeloperoxidase Inactivator: Integration of Preclinical, In Silico, and Biomarker Methodologies in the Prediction of the Clinical Outcome.
Drug Metab Dispos
; 45(5): 501-511, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28254951
17.
Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone.
Diabetes Obes Metab
; 19(5): 721-728, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28116776
18.
Pharmacokinetics and Disposition of the Thiouracil Derivative PF-06282999, an Orally Bioavailable, Irreversible Inactivator of Myeloperoxidase Enzyme, Across Animals and Humans.
Drug Metab Dispos
; 44(2): 209-19, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26608081
19.
Reductions in remnant cholesterol and VLDL cholesterol through inhibition of ANGPTL3 protein synthesis: an analysis from the TRANSLATE-TIMI 70 trial.
Eur J Prev Cardiol
; 2024 Mar 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38484368
20.
Hepatic fat changes with antisense oligonucleotide therapy targeting ANGPTL3.
J Clin Lipidol
; 18(2): e261-e268, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38158248